| Question 1: A major potential source of artifacts in EPID-based VMAT dose reconstruction is: |
| Reference: | McCowan et al. Clinical Implementation of a Model-Based In Vivo Dose Verification System for Stereotactic Body Radiation Therapy-Volumetric Modulated Arc Therapy Treatments Using the Electronic Portal Imaging Device. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1077-1084. |
| Choice A: | Frame-averaging artifacts. |
| Choice B: | Partial volume effects. |
| Choice C: | Kernel artifacts. |
| Choice D: | None of the above. |
| Question 2: One advantage of using EPID over ion-chamber matrix detectors is: |
| Reference: | McCowan et al. Clinical Implementation of a Model-Based In Vivo Dose Verification System for Stereotactic Body Radiation Therapy-Volumetric Modulated Arc Therapy Treatments Using the Electronic Portal Imaging Device. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1077-1084. |
| Choice A: | Water equivalent. |
| Choice B: | Can capture larger treatment fields. |
| Choice C: | Higher resolution. |
| Choice D: | None of the Above. |
| Question 3: What is the purpose of applying a pixel sensitivity map to raw EPID images? |
| Reference: | Greer PB, Correction of pixel sensitivity variation and off-axis response for amorphous silicon EPID dosimetry. Med. Phys. 32 (12), December 2005 |
| Choice A: | Background noise. |
| Choice B: | Ghosting effect. |
| Choice C: | Variations in response across detector panel. |
| Choice D: | All of the above. |
| Choice E: | None of the above. |
| Question 4: Beam profile change measured on 2D detector array (EPID or ionization chamber) is sensitive to photon beam energy change and can be used as metrics for photon energy verification. |
| Reference: | through flatness variation using an ion chamber array. Med Phys 40(4):042101, 2013.
Yaddanapudi, S. et al. Rapid acceptance testing of modern linac using on‐board MV and kV imaging systems. Med. Phys., 44: 3393-3406. (2017)
|
| Choice A: | True. |
| Choice B: | False. |
| Question 5: What does TG-100 recommend for making adjustments to your existing QA program based on new paradigms for quality and safety? |
| Reference: | Huq et al. The report of the Task Group 100 of the AAPM: Application of risk analysis methods to radiation therapy quality management. Med Phys 43(7):4209-4262, 2016. |
| Choice A: | When making large changes to your existing QA program, it is best to do it all at once. |
| Choice B: | You should only make small, incremental changes to your existing QA program over many years. |
| Choice C: | Do not make sudden, major changes to your existing QA program. |
| Choice D: | One should never change their existing QA program. |
| Question 6: When evaluating QA data from equipment or processes against a quality indicator (e.g., daily linac output QA), what is good description of tolerance levels or limits for the quality indicator? |
| Reference: | Pawlicki et al. The Systematic Application of Quality Measures and Process Control in Clinical Radiation Oncology. Semin Radiat Oncol 22:70-76, 2012. |
| Choice A: | A quantitative description of the degree of adherence to a quality indicator. |
| Choice B: | The boundary within which the process is considered operating normally. |
| Choice C: | A requirement for the average performance of a process. |
| Choice D: | The degree to which measured quantities in the clinic are allowed to vary without risking harm to the patients. |
